SNY Sanofi IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1121404 · Reporting currency EUR · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: EUR | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 43.63B | 41.08B | 37.82B | 37.65B | 37.76B |
| Cost of revenue | 13.05B | 13.21B | 12.63B | 11.88B | 12.26B |
| Gross profit | 33.67B | 31.08B | 28.99B | 28.68B | 26.92B |
| R&D expense | 7.84B | 7.39B | 6.51B | 6.50B | 5.69B |
| SG&A expense | 9.54B | 9.18B | 8.93B | 8.74B | 9.55B |
| Operating income | 6.34B | 7.25B | 6.96B | 10.16B | 8.13B |
| Interest expense | 563.00M | 1.07B | 1.29B | 430.00M | 368.00M |
| Income tax | 1.04B | 1.20B | 1.02B | 1.91B | 1.56B |
| Net income | 7.81B | 5.56B | 5.40B | 8.37B | 6.22B |
| EPS (basic) | 6.40 | 4.44 | 4.31 | 6.69 | — |
| EPS (diluted) | 6.37 | 4.43 | 4.30 | 6.66 | — |
| Weighted avg. shares (diluted) | 1.23B | 1.26B | 1.26B | 1.26B | 1.26B |
| Balance sheet | |||||
| Cash & equivalents | 7.66B | 7.44B | 8.71B | 12.74B | 10.10B |
| Receivables | 8.41B | 7.68B | 8.43B | 8.42B | 7.57B |
| Inventory | 10.21B | 9.43B | 9.67B | 8.96B | 8.71B |
| Current assets | 30.95B | 42.59B | 30.67B | 34.11B | — |
| PP&E, netmay include right-of-use assets (IFRS) | 10.05B | 10.09B | 10.16B | 9.87B | 10.03B |
| Goodwill | 41.30B | 43.38B | 49.40B | 49.89B | 48.06B |
| Intangibles | 26.26B | 22.63B | 24.32B | 21.64B | 21.41B |
| Total assets | 126.81B | 132.80B | 126.46B | 126.72B | 120.24B |
| Current liabilities | 28.34B | 29.16B | 24.21B | 23.97B | — |
| Short-term debt | 4.34B | 4.21B | 2.04B | 4.17B | 3.18B |
| Long-term debt | 14.25B | 11.79B | 14.35B | 14.86B | 17.12B |
| Total debt | 18.59B | 16.00B | 16.39B | 19.03B | 20.31B |
| Total liabilities | 55.09B | 54.94B | 52.11B | 51.57B | 51.21B |
| Shareholders' equity | 71.38B | 77.51B | 74.04B | 74.78B | 68.68B |
| Net debt | 10.93B | 8.56B | 7.68B | 6.29B | 10.21B |
| Cash flow statement | |||||
| Operating cash flow | 10.75B | 9.08B | 10.26B | 10.53B | 10.52B |
| Investing cash flow | -2.45B | -4.41B | -6.20B | -2.08B | -7.30B |
| Financing cash flow | -8.21B | -5.76B | -8.05B | -5.82B | -7.06B |
| Stock-based compensation | 313.00M | 278.00M | 260.00M | 234.00M | 244.00M |
| Dividends paid | 4.77B | 4.70B | 4.45B | 4.17B | 4.01B |
| Share buybacks | 5.03B | 302.00M | 593.00M | 497.00M | 382.00M |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.